Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Case 9 Guillain–Barré Syndrome (GBS) and Miller–Fisher Syndrome (MFS)
- Case 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Case 11 IgM Anti-MAG Polyneuropathy
- Case 12 Polyneuropathy, Organomegaly, Endocrine Manifestations, Monoclonal Protein, and Skin Changes (POEMS) Syndrome
- Case 13 Vasculitic Neuropathy
- Case 14 Small-Fibre Neuropathy (SFN)
- Case 15 Sensory Neuronopathy (SNN, Ganglionopathy)
- Case 16 Wartenberg Migrant Sensory Neuropathy
- Case 17 Multifocal Motor Neuropathy (MMN)
- Case 18 Peripheral Nerve Hyperexcitability Syndromes: Morvan Syndrome
- Case 19 Idiopathic Brachial Plexus Neuropathy, Neuralgic Amyotrophy (NA)
- Case 20 Diabetic Neuropathy
- Case 21 Alcoholic Polyneuropathy
- Case 22 Chronic Idiopathic Axonal Polyneuropathy (CIAP)
- Case 23 Critical Illness Polyneuropathy and Myopathy (CIPM)
- Case 24 Drug-Induced Polyneuropathies: Amiodarone Polyneuropathy
- Case 25 Lyme Radiculopathy
- Case 26 Leprosy
- Case 27 Charcot–Marie–Tooth Disease (CMT) Type 1A/Hereditary Neuropathy with Liability for Pressure Palsies (HNPP)
- Case 28 Charcot–Marie–Tooth Disease (CMT) Type 2 A and Type 2B
- Case 29 Hereditary Sensory and Autonomic Neuropathy (HSAN) Type 4
- Case 30 Hereditary Transthyretin (TTR) Amyloidosis
- Disorders of the Neuromuscular Junction
- Myopathies
- Video legends
- Index
- References
Case 24 - Drug-Induced Polyneuropathies: Amiodarone Polyneuropathy
from Peripheral Neuropathies
Published online by Cambridge University Press: 29 November 2024
Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Case 9 Guillain–Barré Syndrome (GBS) and Miller–Fisher Syndrome (MFS)
- Case 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Case 11 IgM Anti-MAG Polyneuropathy
- Case 12 Polyneuropathy, Organomegaly, Endocrine Manifestations, Monoclonal Protein, and Skin Changes (POEMS) Syndrome
- Case 13 Vasculitic Neuropathy
- Case 14 Small-Fibre Neuropathy (SFN)
- Case 15 Sensory Neuronopathy (SNN, Ganglionopathy)
- Case 16 Wartenberg Migrant Sensory Neuropathy
- Case 17 Multifocal Motor Neuropathy (MMN)
- Case 18 Peripheral Nerve Hyperexcitability Syndromes: Morvan Syndrome
- Case 19 Idiopathic Brachial Plexus Neuropathy, Neuralgic Amyotrophy (NA)
- Case 20 Diabetic Neuropathy
- Case 21 Alcoholic Polyneuropathy
- Case 22 Chronic Idiopathic Axonal Polyneuropathy (CIAP)
- Case 23 Critical Illness Polyneuropathy and Myopathy (CIPM)
- Case 24 Drug-Induced Polyneuropathies: Amiodarone Polyneuropathy
- Case 25 Lyme Radiculopathy
- Case 26 Leprosy
- Case 27 Charcot–Marie–Tooth Disease (CMT) Type 1A/Hereditary Neuropathy with Liability for Pressure Palsies (HNPP)
- Case 28 Charcot–Marie–Tooth Disease (CMT) Type 2 A and Type 2B
- Case 29 Hereditary Sensory and Autonomic Neuropathy (HSAN) Type 4
- Case 30 Hereditary Transthyretin (TTR) Amyloidosis
- Disorders of the Neuromuscular Junction
- Myopathies
- Video legends
- Index
- References
Summary
A 76-year-old man complained about progressive dull feelings and weakness of the distal lower limbs that gradually progressed over a couple of months to the proximal legs and the hands. In addition, there was minor myalgia in the proximal muscles. He had had a myocardial infarction with cardiac arrhythmia three years earlier. He was treated with amiodarone afterwards. He did not have visual complaints and was otherwise healthy. He did not drink alcohol or use other drugs. He had not been treated with cytostatic drugs.
- Type
- Chapter
- Information
- Neuromuscular DiseaseA Case-Based Approach, pp. 137 - 138Publisher: Cambridge University PressPrint publication year: 2024
References
Suggested Reading
Orr, CF, Ahlskog, JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66(7):865–869. doi: 10.1001/archneurol.2009.96. PMID: 19597088.CrossRefGoogle ScholarPubMed
Peters, J, Staff, NP. Update on toxic neuropathies. Curr Treat Options Neurol 2022;24(5):203–216. doi: 10.1007/s11940-022-00716-5. Epub 2022 Apr 6. PMID: 36186669; PMCID: PMC9518699.CrossRefGoogle ScholarPubMed
Smyth, D, Kramarz, C, Carr, AS, Rossor, AM, Lunn, MP. Toxic neuropathies: a practical approach. Pract Neurol 2023;23(2):120–130. doi: 10.1136/pn-2022-003444. Epub 2023 Jan 25. PMID: 36697225.CrossRefGoogle ScholarPubMed
Stähli, BE, Schwab, S. Amiodarone-induced skin hyperpigmentation. QJM 2011;104(8):723–724. doi: 10.1093/qjmed/hcq131. Epub 2010 Jul 30. PMID: 20675394.CrossRefGoogle ScholarPubMed
Vassallo, P, Trohman, RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):1312–1322. doi: 10.1001/jama.298.11.1312. PMID: 17878423.CrossRefGoogle ScholarPubMed